|
|
|
| Analysis of usage rationality of anti-neoplastic drugs in pharmacy intravenous admixture services |
| CAI Li CHEN Wen-jing XIAN Bao-zhen |
| Department of Pharmacy,Jiangmen Wuyi Hospital of Traditional Chinese Medicine,Guangdong Province,Jiangmen 529000,China |
|
|
|
|
Abstract Objective To analyze the rationality of anti-neoplastic drugs in pharmacy intravenous admixture services(PIVAS)and reference for the safety and effectiveness of clinical antineoplastic drugs in the future.Methods A retrospective analysis was made on the prescriptions of 2000 groups of antineoplastic drugs prepared by PIVAS in our hospital from August 2014 to August 2017,according to the instructions of various anti-neoplastic drugs,referring to the relevant drug use standards(such as pharmacopoeia,newly compiled pharmacology,China National Prescription Collection,clinical intravenous drug dispensing and use guidelines),as well as the relevant warnings issued by the State Food and Drug Administration (CFDA)and the United States FDA,et al.The dosage and selection of solvents in prescriptions were counted,and the route,dosage,sequence and other irrational drug use of antineoplastic drugs were also counted.The choice of solvent,concentration and infusion time of common antineoplastic drugs were counted.The order of administration of antineoplastic drugs in combination was counted.Results A total of 127 out of 2000 prescriptions were unqualified,accounting for 6.35%,among them,unreasonable solvents accounted for 70.08%(89/127),which showed improper dosage and selection.The irrational rate of anti-neoplastic drugs was 22.05%(28/127),including irrational route of administration,irrational dosage and irrational order of administration.Other unreasonableness accounted for 7.09% (9/127).There were differences in the stability of solvents and liquids used in different antineoplastic drugs,so the clinical infusion time and precautions were different.There was a certain order of administration in the clinical application of antineoplastic drugs.If the order of administration was wrong,it would affect the anti-neoplastic effect of drugs or cause serious adverse reactions.Conclusion There are some unreasonable prescriptions in the use of PIVAS antineoplastic drugs,such as improper solvent dosage,improper selection,irrational route of administration,irrational dosage and irrational order of administration,et al.Hospitals need to strengthen the audit of the above issues to ensure the quality and rational use of antineoplastic drugs.
|
|
|
|
|
|
| [5] |
金有豫，高润霖.中国国家处方集[M].北京：人民军医出版社，2010．
|
| [6] |
陈新谦，金有豫，汤光.新编药物学[M].17版.北京：人民卫生出版社，2011．
|
| [7] |
王羽，张宗久，赵明钢，等.临床静脉用药调配与使用指南[Z].2010：390．
|
| [8] |
夏丽军，陈伟东，徐美华，等.静脉药物配置中心抗肿瘤药物用药情况分析[J].中国药业，2012，21（17）：36-37.
|
| [9] |
陈冰，吴柏雄，崔朴，等.静脉药物配置中心抗肿瘤药物不合理医嘱分析[J].中国现代药物应用，2016，10（7）：273-274.
|
| [10] |
郭江宁，张鹏.静脉药物配置中心抗肿瘤药物不合理使用问题与分析[J].临床合理用药杂志，2014，7（5）：3-4.
|
| [11] |
罗利雄，文会先，胡芳涛，等.静脉药物配置中心抗肿瘤药物不合理医嘱分析[J].中国药物与临床，2012，12（3）：403-404.
|
| [12] |
吴海伟，白羽，刘红，等.我院273例抗肿瘤药物不良反应报告分析[J].中国医药导报，2017，14（14）：126-130.
|
| [13] |
安永恒，丁爱萍，梁军.肿瘤合理用药[M].2版.北京：人民卫生出版社，2009：193，69-71，196.
|
| [14] |
晁青，张亚婷，张晓霞，等.我院静脉药物配置中心抗肿瘤药不合理医嘱审核结果浅析[J].护士进修杂志，2017，32（21）：1952-1955.
|
| [15] |
李静，石庆平，彭德峰.PDCA循环在静脉药物配置中心提高抗肿瘤药物配置质量中的应用[J].中华全科医学，2018，16（12）：2095-2097，2101.
|
| [1] |
刘广宣，赵茜.抗肿瘤药物11 030例处方分析[J].中国医院药学杂志，2011，31（1）：72-73.
|
| [2] |
殷爽，刘丽.环境监测与生物监测在静脉药物配置中心抗肿瘤药物暴露评估中的应用研究[J].中国医学前沿杂志（电子版），2016，8（6）：119-123.
|
| [3] |
王丽春.我院静脉药物配置中心抗肿瘤药物不合理用药分析[J].中国药业，2013，22（3）：21-22.
|
| [4] |
国家药典委员会.中华人民共和国药典：临床用药须知[M].北京：人民卫生出版社，2005．
|
|
|
|
